Novo Nordisk’s Semaglutide Hits Phase III Marks In NASH

 
• By Joseph Haas
  
Novo Nordisk's semaglutide hits both primary endpoints in a Phase III NASH study (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Therapy Areas